Eglaro-S Tablets 15/100Mg (1 Box = 2 Strips) (1 Strip = 7 Tablets)

Ertugliflozin : Ertugliflozin is an inhibitor of SGLT2

PKR 790.00

PKR 750.50

You save: PKR 39.50

Quantity:

SKU: EGLARO_S_15_100MG_TAB_14_S_NV

Category: Medicines

Ertugliflozin : Ertugliflozin is an inhibitor of SGLT2. By inhibiting SGLT2, Ertugliflozin reduces renal reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion. Ertugliflozin also causes an osmotic diuresis, which may result in increase of urinary glucose excretion. Sitagliptin : Sitagliptin improve glycemic control in patients with type 2 diabetes by enhancing the levels of active incretin hormones. Incretin hormones, including glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), In addition, GLP-1 lowers glucagon secretion from pancreatic alpha cells. Decreased glucagon concentrations, along with higher insulin levels, lead to reduced hepatic glucose production, resulting in a decrease in blood glucose levels.

Purpose

Diabetes

Ingredients

Ertugliflozin + Sitagliptin

Warnings

Ertugliflozin causes intravascular volume contraction. Therefore, symptomatic hypotension may occur after initiating Ertugliflozin + Sitagliptin .
Treatment with medicines containing SGLT2 inhibitors increases the risk for urinary tract infections. Evaluate patients for signs and symptoms of urinary tract infections and treat promptly, if indicated.
Ertugliflozin + Sitagliptin who present with signs and symptoms consistent with severe metabolic acidosis is advised to be assessed for ketoacidosis regardless of presenting blood glucose levels, as ketoacidosis associated with Ertugliflozin + Sitagliptin may be present even if blood glucose levels are less than 250mg/dL. If ketoacidosis is suspected, Ertugliflozin + Sitagliptin is advised to be discontinued.

Side Effects

Pancreatitis, hypotension, ketoacidosis, acute kidney injury, impairment in renal function, urosepsis, pyelonephritis, lower limb amputation, heart failure, hypoglycemia with concomitant use with insulin and insulin secretagogues, necrotizing fasciitis of the perineum (fournierâ€™s gangrene), genital mycotic infections, hypersensitivity reactions, increases in low-density lipoprotein, severe and disabling arthralgia, bullous pemphigoid, upper respiratory tract infection, nasopharyngitis, urinary tract infections, vaginal pruritus, increased urination, back pain, weight decreased and headache.